Pharmacoeconomic aspects of the development of myocardial remodeling in patients with type 2 diabetes mellitus
- Authors: Koroleva E.V.1, Khokhlov A.L.1, Sirotkina A.M.1
-
Affiliations:
- Yaroslavl State Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 21, No 4 (2019)
- Pages: 66-69
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/96842
- DOI: https://doi.org/10.26442/20751753.2019.4.190276
- ID: 96842
Cite item
Full Text
Abstract
Aim. Determine the relationship between the treatment and the development of left ventricular myocardial remodeling; conduct a pharmacoeconomic assessment of therapy in patients with type 2 diabetes. Materials and methods. The study included 208 patients with diabetes: group A (retrospective) - 105 patients, group B (prospective) - 103 patients. All patients received hypoglycemic and antihypertensive therapy. To determine the economic feasibility of using the drugs, the cost-effectiveness ratio (CER) was calculated. Results. The frequency of changes in the geometry of the heart increased in the absence of insulin therapy or on the background of PSGP monotherapy, as well as in the absence of ACE inhibitors, ARA II as antihypertensive therapy. NNT analysis showed greater efficacy and safety of alogliptin and empagliflozin. Our clinical and economic study also confirmed the greater efficacy of these drugs, but they turned out to be less economically acceptable compared to biguanides. Conclusion. The results of our study clearly demonstrate the dependence of the development of structural changes in the heart on the treatment of both primary and comorbid pathology in patients with type 2 diabetes, the most effective drugs from the IDPP-4 and AHHP-1 groups, as well as the ACE inhibitor and ARA II.
Full Text
##article.viewOnOriginalSite##About the authors
Elena V. Koroleva
Yaroslavl State Medical University of the Ministry of Health of the Russian Federation
Email: elena-korol2014@yandex.ru
senior laboratory technician Yaroslavl, Russia
Aleksandr L. Khokhlov
Yaroslavl State Medical University of the Ministry of Health of the Russian FederationCorr. Member of RAS, D.Sci. (Med.), Full Prof. Yaroslavl, Russia
Alfiia M. Sirotkina
Yaroslavl State Medical University of the Ministry of Health of the Russian Federation
Email: a.sirotkina@mail.ru
Cand. Sci. (Med.) Yaroslavl, Russia
References
- Kuritzky L et al. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes. Postgrad Med 2014; 126 (6): 60-72.
- Хохлов А.Л., Лисенкова Л.А. Фармакоэпидемиологическое исследование антигипертензивной терапии в пожилом возрасте. Клин. геронтология. 2003; 9 (7): 31-4.
- Сторожаков Г.И. Кардиомиопатии: эволюция взглядов на проблему. Лечебное дело. 2009; 1: 3-12. [Storozhakov G.I. Kardiomiopatii: evoliutsiia vzgliadov na problemu. Lechebnoe delo. 2009; 1: 3-12 (in Russian).]
- Лилеева Е.Г., Хохлов А.Л. Фармакоэпидемиологическое исследование лечения и профилактики гипертонических кризов на догоспитальном этапе. Качественная клин. практика. 2006; 1: 46-50.
- Стародубов В.И., Каграманян И.Н., Хохлов А.Л. и др. Оценка медицинских технологий. Международный опыт. Под ред. В.И.Стародубова, И.Н.Каграманяна. М., 2012.
- Stettler C et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006; 152: 27-38.
- Хохлов А.Л., Кукес В.Г., Сычев Д.А. и др. Персонализированные подходы к лечению заболеваний, связанных с нарушениями липидного обмена и атеросклерозом. М.; Ярославль, 2016.
Supplementary files
